Saturday 17 October 2026
Export ALKS’s income statement to Excel — free account
Alkermes plc
ALKS Healthcare Drug Manufacturers Specialty & Generic
Alkermes plc’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, down 5.25% from fiscal 2024. In the quarter to June 2026, revenue grew 27.0%, EPS fell 99.4% and free cash flow grew 1.13%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
41.22
1.12
+2.79%
Follow ALKS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
14.49 | 19.03 | 38.02 | 130.02 |
P/S ratio |
3.26 | 3.12 | 3.76 | 5.25 | |
P/FCF ratio |
10.09 | 9.57 | 26.57 | 39.30 | |
P/Operating CF |
48.71 | 27.10 | (35.46) | 60.28 | |
P/B ratio |
2.86 | 2.53 | 3.36 | 4.84 | |
Price to Tangible BV |
3.00 | 2.66 | 0.00 | 0.00 | |
EV/Sales |
2.71 | 2.42 | 4.40 | 5.76 | |
EV/EBITDA |
10.63 | 12.73 | 28.20 | 43.12 | |
EV/Operating CF |
7.63 | 6.87 | 26.84 | 38.21 | |
EV/FCF |
8.41 | 7.43 | 31.08 | 43.10 | |
Quick Ratio |
3.09 | 3.04 | 1.53 | 1.68 | |
Current Ratio |
3.67 | 3.55 | 2.27 | 2.30 | |
Net Debt/EBITDA |
(11.44) | (21.30) | (61.92) | 10.63 | |
Debt/Assets |
0.00% | 0.00% | 35.47% | 34.22% | |
Debt/Equity |
0.00 | 0.00 | 0.86 | 0.83 | |
Asset Turnover |
0.68 | 0.65 | 0.49 | 0.50 | |
Operating CF/Net income |
1.23 | 3.45 | 2.49 | 289.79 | |
Capex/Depreciation |
(2.14) | 0.28 | (0.13) | (0.13) | |
Interest Coverage |
— | — | (2.31) | 0.71 | |
Research and Development Expense of Revenue |
20.74% | 24.19% | 26.30% | 22.77% | |
Selling, General and Administrative Expense of Revenue |
43.58% | 48.68% | 67.34% | 43.88% | |
Intangible Assets out of Total Assets |
0.04 | 0.03 | 0.56 | 0.54 | |
Share Based Compensation of Revenue |
6.26% | 6.83% | 9.25% | 6.28% | |
Graham Net Nets |
0.23 | 0.27 | (0.20) | (0.12) | |
Graham Number |
22.11 | 19.11 | 14.85 | 9.91 | |
Earnings Yield |
6.90% | 5.25% | 2.63% | 0.77% | |
Free Cash Flow Yield |
9.91% | 10.45% | 3.76% | 2.54% | |
Revenue per Share |
2.39 | 2.33 | 2.36 | 2.97 | |
Operating CF per Share |
0.62 | 1.03 | (1.00) | 0.87 | |
Capex per Share |
(0.10) | 0.01 | (0.02) | (0.05) | |
Free Cash Flow per Share |
0.51 | 1.04 | (1.02) | 0.82 | |
Cash per Share |
6.73 | 8.01 | 3.08 | 3.93 | |
Shareholders Equity per Share |
10.50 | 11.05 | 10.54 | 10.83 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
10.50 | 11.05 | 10.54 | 10.83 | |
Free Cash Flow |
84.36 | 171.14 | (169.82) | 137.04 | |
Working Capital |
1,267.30 | 1,385.72 | 759.15 | 860.82 | |
Capital Expenditures |
(17.31) | 1.07 | (4.08) | (8.15) | |
Net Current Asset Value |
1,145.58 | 1,261.46 | (1,147.90) | (1,061.67) | |
EV/EBIT |
11.52 | 14.09 | 35.83 | 81.86 | |
Capex to Sales |
0.04 | 0.00 | 0.01 | 0.02 | |
Price to Operating Income |
13.81 | 18.15 | 30.63 | 74.64 | |
| Other line items | |||||
Average Receivables |
360.80 | 359.28 | 363.17 | 405.69 | |
Average Payables |
187.59 | 237.45 | 239.31 | 289.11 | |
Average Inventory |
191.04 | 189.76 | 260.07 | 245.44 | |
Average Assets |
2,242.40 | 2,271.28 | 3,170.03 | 3,322.97 | |
Average Common Equity |
1,512.77 | 1,642.14 | 1,631.56 | 1,716.57 |
Columns are period end dates